CAR-T Therapy Demonstrates Significant Reduction in Multiple Myeloma Disease Burden

Key Insights

• Data from the CARTITUDE-4 clinical trial indicates that CAR-T therapy shows improved outcomes compared to standard of care for multiple myeloma patients.
• Cerebrospinal fluid (CSF) analyses from patients treated with a novel therapy showed over 80% reduction in NAA levels from baseline, suggesting significant therapeutic impact.
• Anixa Biosciences received clearance for a single-patient investigational new drug application to redose a patient in a clinical trial, allowing for extended evaluation.

CAR-T therapy is demonstrating promising results in reducing disease burden in multiple myeloma patients, according to data from the CARTITUDE-4 clinical trial. The trial compared outcomes of patients treated with CAR-T therapy to those receiving standard of care, revealing significant improvements in the CAR-T arm.

Impact on NAA Levels in CSF

In a separate study, cerebrospinal fluid (CSF) analyses from seven patients treated with an innovative therapeutic approach showed substantial reductions in N-acetylaspartate (NAA) levels. Specifically, NAA levels decreased by more than 80% from baseline in these patients. This reduction suggests a significant impact on disease activity within the central nervous system.

Anixa Biosciences' Redosing Strategy

Anixa Biosciences has obtained clearance for a single-patient investigational new drug (IND) application, enabling the redosing of a patient within a clinical trial. This redosing strategy allows for extended evaluation of the therapy's long-term effects and potential benefits in individual cases.